GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

Af­ter large­ly whiff­ing the past 2 years on the phar­ma R&D front, Glax­o­SmithK­line re­search chief Hal Bar­ron has seized boast­ing rights to a key win that puts them back in the can­cer drug de­vel­op­ment game.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER